Personal Products Co.'s Monistat(R) 1 (300 mg of tioconazole ointment in a prefilled applicator) has been approved for marketing in the United States as a one-dose treatment of vaginal yeast infection. Tioconazole has a similar safety and efficacy profile and is in the same chemical family as the miconazole in Monistat(r) 3 and Monistat(r) 7. The one-dose topical treatment has the advantage over one-dose oral therapies in that systemic absorption, and thus the chances of side effects (gastrointestinal distress and changes in liver function) and drug interactions (specifically with hypoglycemics and antihistamines) are minimized.
COPYRIGHT 1998 Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
COPYRIGHT 2004 Gale Group